Skip to Content

Continuing Education

Oral Oncolytics in Focus: Updates on New Approved Therapies

Best Suited For: Pharmacist, Pharmacy Technician

CE Credits: 1 hours

Related Topics: New Drug Approvals

Description

The purpose of this CE presentation is to provide updates in new oral oncolytic agents that were approved in 2024. The presentation will review the mechanism of action, indication, dosing, clinical trial, adverse events, and additional clinical pearls for vorasidenib, lazertinib, inavolisib, and revumenib.

Pricing

This activity does not require payment to register.

This course has expired.

View our full list of NCODA courses or check the webinar recordings for more to discover.